Insufficient lymph node dissection is an independent risk factor for postoperative cancer death in patients undergoing surgery for stage II colorectal cancer

European Surgical Research

Volumn 46, Issue 2, 2011, Pages 57-64

  Ishizuka, M ^a   Nagata, H ^a   Takagi, K ^a   Kubota, K ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer surgery; Lymph node dissection; Risk factor analysis; Stage II colorectal cancer

Indexed keywords

ALBUMIN;

AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CHI SQUARE TEST; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; UNIVARIATE ANALYSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPOALBUMINEMIA; JAPAN; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN;

EID: 78649698741     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321318     Document Type: Article

References (41)

1. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al.: Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44: 904-912. (Pubitemid 41780118)
2. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20: 3999-4005.
3. Law WL, Ho JW, Chan R, Au G, Chu KW: Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy. Dis Colon Rectum 2005; 48: 218-226. (Pubitemid 40576550)
4. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
5. Schippinger W, Samonigg H, Schberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, et al.: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007; 97: 1021-1027. (Pubitemid 47587021)
6. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, et al.: Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 2008; 26: 2336-2341.
7. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-1310.
8. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P: Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44: 1682-1688. (Pubitemid 33126988)
9. Petersen VC, Baxter KJ, Love SB, Shepherd NA: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-69. (Pubitemid 34717746)
10. Graziano F, Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 1026-1038. (Pubitemid 36950166)
11. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806. (Pubitemid 41095169)
12. Morris M, Platell CF: Surgical volume influences survival in patients undergoing resections for stage II colon cancers. ANZ J Surg 2007; 77: 902-906. (Pubitemid 47353076)
13. Cianchi F, Messerini L, Comin CE, Boddi V, Perna F, Peigli G, et al.: Pathologic determinants of survival after resection of T3N0 (Stage IIA) colorectal cancer: proposal for a new prognostic model. Dis Colon Rectum 2007; 50: 1332-1341. (Pubitemid 47472384)
14. Meng WJ, Sun XF, Tian C, Wang L, Yu YY, Zhou B, et al.: Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients. Oncology 2007; 72: 82-88. (Pubitemid 350249134)
15. Tsai HL, Lu CY, Hsieh JS, Wu DC, Jan CM, Chai CY, et al.: The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. J Gastrointest Surg 2007; 11: 660-665.
16. Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, et al.: Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg 2007; 246: 1040-1046.
17. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M: Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008; 51: 568-572.
18. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, et al.: Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51: 503-507.
19. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Koike Y, Yokoe T, et al.: Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol 2008; 15: 1617-1624.
20. Tsai HL, Cheng KI, Lu CY, Kuo CH, Ma CJ, Wu JY, et al.: Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection. J Surg Oncol 2008; 97: 383-387.
21. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, et al.: Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008; 112: 495-502. (Pubitemid 351186190)
22. Japanese Classification of Colorectal Carcinoma. Japanese Society for Cancer of the Colong and Rectum ed 2. Tokyo, Kanehara & Co. Ltd.
23. Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al.: Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis 2010; 25: 681-686.
24. Fujita S, Yamamoto S, Akasu T, Moriya Y: Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis 2008; 23: 1073-1079.
25. Leitch EF, Chakrabarti M, Crozier JE, Mc- Kee RF, Anderson JH, Horgan PG, et al.: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007; 97: 1266-1270. (Pubitemid 350035815)
26. Stor Z, Frkovic GS, Bracko M, Repse S: Prognostic value of clinical, pathological and immunohistochemical markers in stage II colon cancer patients. Acta Chir lugosl 2008; 55: 39-44.
27. Comella P: A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag 2007; 3: 421-431. (Pubitemid 47214982)
28. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, Mizobe T, et al.: The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 2006; 57: 577-583. (Pubitemid 43237841)
29. Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S: An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. Surgery 2007; 142: 741-748. (Pubitemid 350018847)
30. Sarli L, Bader G, Iusco D, Salvemini C, Mauro DD, Mazzeo A, et al.: Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005; 41: 272-279. (Pubitemid 40126960)
31. Yoshimatsu K, Ishibashi K, Umehara A, Yokomizo H, Yoshida K, Fujimoto T, et al.: How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate. Hepatogastroenterology 2005; 52: 1703-1706. (Pubitemid 41745615)
32. Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC: For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83: 666-672. (Pubitemid 28387688)
33. Cianchi F, Palomba A, Boddi V, Messerini L, Pucciani F, Perigli G, et al.: Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined. World J Surg 2002; 26: 384-389. (Pubitemid 36920420)
34. Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A, et al.: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235: 458-463. (Pubitemid 34258343)
35. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT- 0089. J Clin Oncol 2003; 21: 2912-2919. (Pubitemid 46621841)
36. Swanson RS, Compton CC, Stewart AK, Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65-71.
37. Berberoglu U: Prognostic significance of total lymph node number in patients with T1- 4N0M0 colorectal cancer. Hepatogastroenterology 2004; 51: 1689-1693. (Pubitemid 39389760)
38. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA: Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005; 97: 219-225. (Pubitemid 40277372)
39. Compton CC: Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007; 13: 6862-6870.
40. Evans MD, Barton K, Rees A, Stamatakis JD, Karandikar SS: The impact of surgeon and pathologist on lymph node retrieval in colorectal cancer and its impact on survival for patients with Dukes' stage B disease. Colorectal Dis 2008; 10: 157-164.
41. Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS: Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17: 2896-2900. (Pubitemid 29415250)